Document Detail

Garlicin attenuates reperfusion no-reflow in a catheter-based porcine model of acute myocardial infarction.
MedLine Citation:
PMID:  22471597     Owner:  NLM     Status:  Publisher    
Objective: To evaluate whether garlicin can attenuate reperfusion no-reflow in a catheter-based porcine model of acute myocardial infarction (AMI). Methods: Twenty-two swine were used: six in a sham-operation group, and eight each in the control and garlicin groups. The distal part of the left anterior descending coronary artery (LAD) in the latter two groups was occluded by a dilated balloon for 2 hr, then reperfused for 3 hr. Garlicin (1.88mg/kg) was injected just before reperfusion until reperfusion for 1 hr in the garlicin group. Hemodynamic data were examined before AMI, 2 hr after occlusion, and 3 hr after reperfusion. Myocardial contrast echocardiography (MCE) and pathological staining were performed to evaluate the myocardial no-reflow area (NRA). Serum proinflammatory cytokines and endothelin (ET)-1 were examined by radioimmunoassay. Results: Left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) significantly improved in the garlicin group after reperfusion compared with the control group and also 2hr after AMI (p<0.05 for both). MCE and pathological staining both showed garlicin attenuated reperfusion NRA after AMI (p<0.05, p<0.01). Garlicin not only decreased serum interleukin (IL)-6 and tumor necrosis factor (TNF)-α after reperfusion (p<0.05 for both), but also ET-1 level (p<0.01). Conclusion: Garlicin attenuated reperfusion no-reflow in our catheter-based porcrine model of AMI, possibly through decreasing serum proinflammatory cytokines and ET-1.
Yang Peng; Li Jiahui; Li Aili; Wang Yong; Shi Zaixiang; Ke Yuannan; Li Xianlun
Related Documents :
25082847 - Erythropoietin priming improves the vasculogenic potential of g-csf mobilized human per...
12607707 - Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury.
17965927 - The cardioprotective effect of necrostatin requires the cyclophilin-d component of the ...
9500877 - Monophosphoryl lipid a induces delayed preconditioning against cardiac ischemia-reperfu...
11369007 - Type a behavior and coronary atherosclerosis.
16231627 - Extracorporeal membrane oxygenation to cardiopulmonary bypass with a single circuit exp...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-3
Journal Detail:
Title:  Artificial cells, blood substitutes, and immobilization biotechnology     Volume:  -     ISSN:  1532-4184     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431307     Medline TA:  Artif Cells Blood Substit Immobil Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Cardiology, China-Japan Friendship Hospital , Beijing , China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Investigation of the simultaneous production of superoxide dismutase and catalase enzymes from Rhodo...
Next Document:  Determination of normal value of glomerular size in Chinese adults by different measurement methods.